Trial Profile
A Phase 2, Open-label Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Sep 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Rucaparib (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ARIES
- Sponsors Clovis Oncology [CEASED]; zr pharma
- 17 Dec 2020 Status changed from active, no longer recruiting to discontinued.
- 11 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 25 Jun 2019 Status changed from not yet recruiting to recruiting.